About
Helen S. Kim has served on Aktis Oncology's board of directors since February 2021. She is a Senior Managing Director of Vida Ventures and was previously a Partner at The Column Group and Executive Vice President of Business Development at Kite Pharma, where she led the corporate development that resulted in its acquisition by Gilead. She currently serves on the boards of Prothena and several private biotechnology companies, and received a BS in Chemical Engineering from Northwestern University and an MBA from the University of Chicago.
Roles
Aktis Oncology, Inc.
Director · Current role
February 2021–present
Vida Ventures, LLC
Senior Managing Director
April 2019 - present
The Column Group
Partner
March 2018 - March 2019
Kite Pharma, Inc.
Executive Vice President, Business Development · Led corporate development resulting in acquisition by Gilead in 2017
June 2014 - January 2018
External Roles
Prothena Corporation plc
Director
August 2022 - present
Also at Aktis Oncology, Inc.
See how Top Bucket AI works for your firm
Request DemoTop Bucket AI Research
Stay ahead of private markets
Research and market intelligence for private-markets professionals.
✓
You're subscribed.
Thanks for signing up.